comparing cardiovascular and kidney outcomes with tirzepatide vs. glp-1 agonists Beyond glycemia: to analogues | Reviews in Endocrine Metabolic Disorders The cardiovascular effects of GLP-1

352 Lebrec, J

Notably, astrocytes are more efficient at oxidizing long-chain FAs than neurons

For both injection and tablet formulations, a gradual doseescalation schedule over approximately 16 weeks (injection) or 90 days (tablets) is standard to improve GI tolerability. For prescribers , key considerations include: Confirming that the intended use is FDAapproved (CV risk reduction, chronic weight management, or adult MASH with F2F3 fibrosis) and that BMI and comorbidity criteria are met. Excluding contraindications (MTC/MEN 2, prior anaphylaxis/angioedema to semaglutide) and identifying risk factors such as prior pancreatitis, gallbladder disease, severe GI motility disorders, and advanced diabetic retinopathy

Takviye kullanmadan nce doktorunuza danmanz nerilir